Y-mAbs Therapeutics Inc
Change company Symbol lookup
Select an option...
YMAB Y-mAbs Therapeutics Inc
MTP Midatech Pharma PLC
DFUSX DFA U.S. Large Company Portfolio
THST Truett-Hurst Inc
GPN Global Payments Inc
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Y-mAbs Therapeutics, Inc. is a commercial-stage clinical biopharmaceutical company. It is focused on development and commercialization of antibody based therapeutic products for the treatment of cancer. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The Company’s product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA, which is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops Omburtamab, which is novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB, and in relapsed osteosarcoma.

Closing Price
$3.04
Day's Change
0.19 (6.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.06
Day's Low
2.70
Volume
(Heavy Day)
Volume:
435,993

10-day average volume:
313,454
435,993
  • Prev Close
    2.85
  • Today's Open
    2.86
  • Day's Range
    2.70-3.06
  • Avg Vol (10-day)
    313.5K
  • Last (time)
    4:00p ET 03/24/23
  • Last (size)
    5.9K
  • 52-Wk Range
    2.70 - 20.48
    LowHigh
  • (08/08/22 - 03/24/23)
    12.59%
  • 129.4%
  • Market Cap
    132.8M
  • Shares Outstanding
    43.7M
  • -3.06
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.7
  • 54.64
  • (% of float 02/28/23)
    4.66

Latest News

March 21, 2023
4:01 pm ET
Globe Newswire
March 20, 2023
12:05 pm ET
Globe Newswire
10:22 am ET
Accesswire
9:31 am ET
Newsfile
9:03 am ET
Newsfile
7:31 am ET
Newsfile
5:45 am ET
PR Newswire
March 19, 2023
8:00 pm ET
Accesswire
11:53 am ET
Newsfile
9:16 am ET
Newsfile
7:18 am ET
Newsfile
March 18, 2023
9:00 pm ET
Accesswire
7:10 pm ET
Accesswire
3:30 pm ET
Accesswire
March 17, 2023
8:00 pm ET
BusinessWire
7:59 pm ET
Newsfile
5:46 pm ET
Newsfile
4:19 pm ET
Globe Newswire
1:22 pm ET
Newsfile
11:40 am ET
Newsfile
11:20 am ET
Globe Newswire
10:01 am ET
Newsfile
10:00 am ET
BusinessWire
9:31 am ET
Newsfile
9:19 am ET
Newsfile
8:04 am ET
Newsfile
5:45 am ET
PR Newswire
March 16, 2023
10:51 pm ET
Accesswire
7:58 pm ET
Newsfile
5:38 pm ET
Newsfile
12:31 pm ET
Newsfile
12:17 pm ET
Globe Newswire
11:36 am ET
Newsfile
8:03 am ET
Newsfile
5:45 am ET
PR Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.